OMENN GILBERT S — SEC insider filings
SEC reporting owner CIK 1184227. 38 insider filings on record with FilingPulse; latest filed 2026-10-02.
Transaction summary — filings shown
Covers all 38 filings on record, filed 2020-09-29 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings — 39,333 shares, $128,824 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 48.
- Largest priced transaction: purchase of 20,000 shares @ $5.00 ($100,000) in Amesite Inc., filed 2020-09-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Amesite Inc. (AMST) | Director | 28 | 4 legs · 39,333 sh · $128,824 | — | 32 |
| Angion Biomedica Corp. (ANGN) | Director | 3 | — | — | 8 |
| GALECTIN THERAPEUTICS INC (GALT) | Director | 7 | — | — | 8 |
Insider filings — OMENN GILBERT S
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | Amesite Inc. (AMST) | Grant/award (A): 12,121 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Amesite Inc. (AMST) | Grant/award (A): 9,023 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Amesite Inc. (AMST) | Grant/award (A): 6,522 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Amesite Inc. (AMST) | Option exercise (M): 41,322 · Option exercise (M): 41,322 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Amesite Inc. (AMST) | Grant/award (A): 49,751 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | GALECTIN THERAPEUTICS INC (GALT) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Amesite Inc. (AMST) | Grant/award (A): 6,349 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Amesite Inc. (AMST) | Grant/award (A): 3,934 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Amesite Inc. (AMST) | Grant/award (A): 4,461 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Amesite Inc. (AMST) | Grant/award (A): 4,959 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Amesite Inc. (AMST) | Option exercise (M): 14,620 · Grant/award (A): 41,322 · Option exercise (M): 14,620 (derivative) @ $0 · Grant/award (A): 41,322 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | GALECTIN THERAPEUTICS INC (GALT) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | GALECTIN THERAPEUTICS INC (GALT) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-01-16 | 4 | Amesite Inc. (AMST) | Option exercise (M): 36,630 · Option exercise (M): 36,630 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Amesite Inc. (AMST) | Purchase (P): 3,333 @ $3 | EDGAR |
| 2025-01-03 | 4 | Amesite Inc. (AMST) | Grant/award (A): 2,526 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | Amesite Inc. (AMST) | Grant/award (A): 4,898 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Amesite Inc. (AMST) | Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2024-04-01 | 4 | Amesite Inc. (AMST) | Grant/award (A): 5,381 (derivative) @ $0 | EDGAR |
| 2024-02-07 | 4 | GALECTIN THERAPEUTICS INC (GALT) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | Amesite Inc. (AMST) | Grant/award (A): 36,630 (derivative) @ $0 | EDGAR |
| 2024-01-03 | 4 | Amesite Inc. (AMST) | Grant/award (A): 5,333 (derivative) @ $0 | EDGAR |
| 2023-10-03 | 4 | Amesite Inc. (AMST) | Grant/award (A): 4,706 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | Amesite Inc. (AMST) | Grant/award (A): 3,324 (derivative) @ $0 | EDGAR |
| 2023-04-04 | 4 | Amesite Inc. (AMST) | Grant/award (A): 4,598 (derivative) @ $0 | EDGAR |
| 2023-01-30 | 4 | GALECTIN THERAPEUTICS INC (GALT) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Amesite Inc. (AMST) | Grant/award (A): 68,571 (derivative) @ $0 | EDGAR |
| 2022-10-03 | 4 | Amesite Inc. (AMST) | Grant/award (A): 49,793 (derivative) @ $0 | EDGAR |
| 2022-07-05 | 4/A | Amesite Inc. (AMST) | Grant/award (A): 21,053 (derivative) @ $0 | EDGAR |
| 2022-07-05 | 4 | Amesite Inc. (AMST) | Grant/award (A): 26,087 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Angion Biomedica Corp. (ANGN) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Amesite Inc. (AMST) | Grant/award (A): 9,184 (derivative) @ $0 · Grant/award (A): 175,439 (derivative) @ $0 · Grant/award (A): 84,211 (derivative) @ $0 | EDGAR |
| 2022-01-25 | 4 | GALECTIN THERAPEUTICS INC (GALT) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-12-15 | 4 | Amesite Inc. (AMST) | Purchase (P): 8,000 @ $1.18 · Purchase (P): 8,000 @ $1.17 | EDGAR |
| 2021-03-29 | 4 | GALECTIN THERAPEUTICS INC (GALT) | Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2021-03-10 | 4 | Angion Biomedica Corp. (ANGN) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-02-11 | 4 | Angion Biomedica Corp. (ANGN) | Conversion (C): 23,483 @ $11.57 · Conversion (C): 23,391 @ $11.57 · Conversion (C): 14,783 @ $11.57 · Conversion (C) @ $0 · Conversion (C) @ $0 · Conversion (C) @ $0 | EDGAR |
| 2020-09-29 | 4 | Amesite Inc. (AMST) | Purchase (P): 20,000 @ $5 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1184227 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs